Clinical Trial Update: A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two oral dosing regimens of fidrisertib (IPN60130) for fibrodysplasia ossificans progressiva has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrodysplasia Ossificans Progressiva

Drugs mentioned

• Fidrisertib (fidrisertib)

Snippet

Sponsor: Clementia Pharmaceuticals Inc. | Conditions: Fibrodysplasia Ossificans Progressiva | Phase 2 | Status: TERMINATED